MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 227 filers reported holding MYRIAD GENETICS INC in Q3 2016. The put-call ratio across all filers is 1.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $16,708,000 | -68.6% | 613,594 | -66.9% | 0.12% | -70.4% |
| Q3 2019 | $53,136,000 | -37.8% | 1,855,962 | -39.7% | 0.42% | -35.5% |
| Q2 2019 | $85,484,000 | -23.5% | 3,077,184 | -8.5% | 0.64% | -18.8% |
| Q1 2019 | $111,684,000 | +19.2% | 3,363,970 | +4.4% | 0.79% | +4.9% |
| Q4 2018 | $93,709,000 | -20.9% | 3,223,566 | +25.2% | 0.76% | -0.8% |
| Q3 2018 | $118,485,000 | +33.4% | 2,575,754 | +8.4% | 0.76% | +21.3% |
| Q2 2018 | $88,826,000 | +49.2% | 2,376,935 | +18.0% | 0.63% | +45.3% |
| Q1 2018 | $59,517,000 | -11.4% | 2,014,114 | +3.0% | 0.43% | -11.8% |
| Q4 2017 | $67,174,000 | -30.9% | 1,955,867 | -27.2% | 0.49% | -30.0% |
| Q3 2017 | $97,170,000 | +24.0% | 2,685,733 | -11.5% | 0.70% | +22.6% |
| Q2 2017 | $78,383,000 | +32.7% | 3,033,388 | -1.4% | 0.57% | +31.2% |
| Q1 2017 | $59,058,000 | +16.8% | 3,075,954 | +1.4% | 0.44% | +12.1% |
| Q4 2016 | $50,585,000 | +1.2% | 3,034,522 | +25.0% | 0.39% | -2.8% |
| Q3 2016 | $49,961,000 | -10.8% | 2,427,625 | +32.6% | 0.40% | -13.0% |
| Q2 2016 | $56,029,000 | -28.5% | 1,831,028 | -12.5% | 0.46% | -26.3% |
| Q1 2016 | $78,358,000 | -9.1% | 2,093,457 | +4.8% | 0.62% | -12.6% |
| Q4 2015 | $86,223,000 | +41.1% | 1,997,741 | +22.5% | 0.71% | +38.9% |
| Q3 2015 | $61,102,000 | +58.2% | 1,630,262 | +43.5% | 0.51% | +85.6% |
| Q2 2015 | $38,613,000 | +0.7% | 1,136,006 | +4.9% | 0.28% | 0.0% |
| Q1 2015 | $38,342,000 | +11.5% | 1,083,112 | +7.3% | 0.28% | +9.5% |
| Q4 2014 | $34,381,000 | -13.6% | 1,009,418 | -2.2% | 0.25% | -20.9% |
| Q3 2014 | $39,797,000 | -0.8% | 1,031,801 | +0.1% | 0.32% | +8.5% |
| Q2 2014 | $40,098,000 | +19.9% | 1,030,270 | +5.3% | 0.30% | +21.9% |
| Q1 2014 | $33,441,000 | +195.0% | 978,105 | +81.0% | 0.24% | +188.1% |
| Q4 2013 | $11,336,000 | -11.8% | 540,308 | -1.3% | 0.08% | -15.2% |
| Q3 2013 | $12,859,000 | +0.9% | 547,198 | +15.3% | 0.10% | -6.6% |
| Q2 2013 | $12,748,000 | – | 474,438 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |